APYX

APYX

USD

Apyx Medical Corporation Common Stock

$0.905+0.019 (2.087%)

Prix en Temps Réel

Healthcare
Dispositifs médicaux
États-Unis

Graphique des Prix

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$0.886

Haut

$0.905

Bas

$0.886

Volume

0.00M

Fondamentaux de l'Entreprise

Capitalisation Boursière

34.9M

Industrie

Dispositifs médicaux

Pays

United States

Statistiques de Trading

Volume Moyen

0.05M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $0.755Actuel $0.905Haut $1.99

Rapport d'Analyse IA

Dernière mise à jour: 22 avr. 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

APYX (Apyx Medical Corporation): News, Price Moves, and What to Watch Now

Stock Symbol: APYX Generate Date: 2025-04-22 09:54:26

Alright, let's take a look at Apyx Medical (APYX). This company is in the medical device world, and their stock has been doing some interesting things lately. We've got some news, price history, and even what the AI is predicting. Let's break it down without the jargon.

Recent News Buzz: A Bit of Good News in the Mix

The latest news is from mid-March, and it's about their financial results for last year and the last quarter of 2024. The headline is pretty standard corporate stuff, but digging in, there's a key positive point: they shipped more of their single-use handpieces than expected in the last quarter. Specifically, shipments went up 5% overall, and a solid 20% jump in the US compared to the same time the year before. That's generally a good sign – it means more doctors are using their products.

They also mentioned submitting something to the FDA, a "510(k) premarket notification." In plain English, this is a step towards getting approval for a medical device. It's not a guarantee of approval, but it's a necessary step and shows they're working on bringing new things to market.

Overall vibe from the news? Mildly positive. The company seems to be doing better on product shipments, which is a direct measure of sales, and they're moving forward with regulatory processes. No major negative surprises in this news.

Price Check: A Rocky Ride Lately

Looking at the stock price over the last month or so, it's been a bit of a rollercoaster. If you glance at the numbers, you'll see a general downtrend starting from late January and going through early March. The price was bouncing around in the $1.40-$1.50 range in late January and February, but then it started to slide downwards, hitting lows around $1.00 - $1.10 in early to mid-March. There was a bit of a bounce back up in late March, but then another drop in early April, especially a big plunge around April 4th. Since then, it seems to have stabilized a bit, hovering around the $0.90-$1.00 level.

So, the recent trend? Definitely downwards overall, with a lot of volatility. It's been choppy, not a smooth ride at all.

Now, where are we now compared to this trend? The last data point we have (April 21st) is around $0.94. This is near the recent lows, suggesting the stock is still in a weaker position compared to where it was a month ago.

What about the AI's predictions for the next few days? They're predicting basically no change today, a tiny bump up tomorrow (0.77%), and a tiny dip the day after (-0.51%). Essentially, the AI is not expecting any big moves in the immediate short term. It's predicting more of the same sideways action.

Outlook & Strategy Ideas: Cautious Optimism, But Watch Closely

Putting it all together, what does this suggest?

The news is slightly positive, hinting at some operational improvements. However, the stock price has been under pressure recently, and the AI isn't forecasting a dramatic turnaround right away.

Near-term leaning? Neutral to cautiously optimistic. The positive news about shipments could be a sign that things are starting to improve for Apyx. The price drop might have created an opportunity if you believe in the company's long-term potential. However, the downward price trend and recent volatility are definitely reasons to be careful.

Potential Entry Consideration? If you were thinking about getting into APYX, the current price range around $0.90 - $1.00 might be an area to consider, if you're comfortable with higher risk. Why? Because it's near recent lows, and the AI recommendation data (which we haven't focused on heavily here but is available) actually flags it as potentially undervalued and showing "bullish momentum" based on some technical indicators. The recommendation even suggests entry points around $0.94-$0.99. But, and this is a big but, remember the price has been falling, so there's no guarantee it won't go lower.

Potential Exit/Stop-Loss Consideration? If you did buy around these levels, setting a stop-loss is crucial to manage risk. A stop-loss around $0.89 (as suggested in the recommendation data) could be a level to consider. This is just below recent lows and would help limit your losses if the stock continues to decline. For taking profits, the recommendation mentions a "take-profit" level of $1.26. This is significantly higher than the current price and would represent a good gain if the stock were to move upwards. However, reaching that level is not guaranteed, especially given the recent price action.

Important Note: These are just potential ideas based on the data. The market is unpredictable, and stock prices can move for many reasons.

Company Context: Medical Devices & Cosmetic Surgery

Just a quick reminder about what Apyx Medical actually does. They make medical devices, specifically energy-based surgical tools. They have products used in cosmetic surgery (Renuvion brand) and in hospitals for general surgery (J-Plasma brand). The fact that their handpiece shipments are up is relevant because these are the consumable parts of their systems, meaning more procedures are likely being done using their technology.

In short, APYX is a smaller medical device company in a competitive sector. The recent news is a positive signal, but the stock price has been weak. It's a situation that requires careful monitoring and is definitely not a low-risk investment.

Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in the stock market involves risk, and you could lose money. Always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Actualités Connexes

GlobeNewswire

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and

Voir plus
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Prédiction IABeta

Recommandation IA

Haussier

Mis à jour le: 28 avr. 2025, 19:32

BaissierNeutreHaussier

57.1% Confiance

Risque et Trading

Niveau de Risque4/5
Risque Élevé
Adapté Pour
AgressifValeur
Guide de Trading

Point d'Entrée

$0.85

Prise de Bénéfices

$1.16

Stop Loss

$0.80

Facteurs Clés

Le PDI 38.0 est au-dessus du MDI 37.5 avec un ADX de 11.0, suggérant une tendance haussière
Le MACD -0.0082 est au-dessus de la ligne de signal -0.0117, indiquant un croisement haussier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.